Issues of regret in women with contralateral prophylactic mastectomies

Annals of Surgical Oncology

Volumn 6, Issue 6, 1999, Pages 546-552

  Montgomery, Leslie L ^a   Tran, Katherine N ^a   Heelan, Melissa C ^a   Van Zee, Kimberly J ^a   Massie, Mary Jane ^a   Payne, David K ^a   Borgen, Patrick I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Contralateral breast cancer; Prophylactic mastectomy

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PATIENT ATTITUDE; PATIENT SATISFACTION; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EMOTIONS; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; SURGICAL PROCEDURES, ELECTIVE; UNITED STATES;

EID: 0032869353     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0542-1     Document Type: Article

References (49)

1. Hartman LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
2. Hartmann L, Jenkins R, Schaid D, Yang P. Prophylactic mastectomy: preliminary retrospective cohort analysis. Proc Am Assoc Cancer Res 1997;88:168.
3. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results form 214 families. Am J Hum Genet 1993;52:678-701.
4. Easton DF, Ford D, Bishop DT, The Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-71.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldar DE, the Breast Cancer Linkage Consortium. Risks of cancer in BRCAl-mutation carriers. Lancet 1994;343:692-5.
6. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71.
7. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCAl-positive and BRCA2-positive patients. J Clin Oncol 1998;16:979-85.
8. Houn F, Helzsouer KJ, Friedman NB, Stefanek ME. The practice of prophylactic mastectomy: A survey of Maryland surgeons. Am J Public Health 1995;85:801-5.
9. Fisher ER, Fisher B, Sass R, Wickerham L, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No. 4). Cancer 1984;54:3002-11.
10. Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I and stage II patients with 20-year follow-up. Surgery 1989;106:904-10.
11. Healey EA, Cook F, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993;11:1545-52.
12. Wanebo HJ, Senofsky GM, Fechner RE, Kaiser D, Lynn S, Paradies J. Bilateral breast cancer: risk reduction by contralateral biopsy. Ann Surg 1985;201:667-77.
13. Simkovich AH, Sclafani LM, Masri M, Kinne DW. Role of contralateral breast biopsy in infiltrating lobular cancer. Surgery 1993; 114:555-7.
14. Singletary SE, Taylor SH, Guinee VF, Whitworth PW. Occurrence and prognosis of contralateral carcinoma of the breast. J Am Coll Surg 1994;178:390-6.
15. Robinson E, Rennert G, Rennert HS, Neugut AI. Survival of first and second primary breast cancer. Cancer 1993;71:172-6.
16. Baker RR, Kuhajda FP. The clinical management of a normal contralateral breast in patients with lobular breast cancer. Ann Surg 1989;210:444-8.
17. Smith BL, Bertagnolli M, Klein BB, Batter S, Chang M, Douville LM, Eberlein TJ. Evaluation of the contralateral breast: the role of biopsy at the time of treatment of primary breast cancer. Ann Surg 1992;216:17-21.
18. Lee JSY, Grant CS, Donohue JH, Crotty TB, Harmsen WS, Ilstrup DM. Arguments against routine contralateral mastectomy or undi rected biopsy for invasive lobular breast cancer. Surgery 1995;118: 640-8.
19. Mulvihill JJ, Safyer AW, Bening JK. Prevention in familial breast cancer: counseling and prophylactic mastectomy. Prev Med 1982; 11:500-11.
20. Borgen PI, Hill AD, Tran KN, VanZee KJ, Massie MJ, Payne D, Biggs CG. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998;5:603-6.
21. Cook LS, White E, Schwartz SM, McKnight B, Daling JR, Weiss NS. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 1996;7:382-90.
22. Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578-83.
23. Lopez MJ, Porter KA. The current role of prophylactic mastectomy. Surg Clin North Am 1996;76:231-42.
24. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991;14:451-4.
25. Gershenwald JE, Hunt KK, Kroll SS, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol 1998;5:529-38.
26. Temple WJ, Lindsay RL, Magi E, Urbanski SJ. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 1991;161:413-5.
27. Calson GW, Grossi N, Lewis MM, Temple JR, Styblo TM. Preservation of the inframammary fold: what are we leaving behind? Plast Reconstr Surg 1996;98:447-50.
28. Stems EE, Fletcher WA. Bilateral cancer of the breast: a review of clinical, histologic and immunologic characteristics. Surgery 1991; 110:617-22.
29. Harris RE, Lynch HT, Guirgis HA. Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 1978;60:955-60.
30. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah population database. JAMA 1993;270:1563-8.
31. Lesser ML, Rosen PP, Kinne DW. Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982;91:234-40.
32. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9.
33. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
34. Yeatmen TJ, Lyman GH, Smith SK, Reinigen DS, Cantor AB, Cox CE. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol 1997;4:198-202.
35. Chung MA, Cole B, Wanebo HJ, Bland KI, Chang HR. Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 1997;4:545-50.
36. Cody HS. Routine contralateral breast biopsy: helpful or irrelevant? Ann Surg 1997;225:370-6.
37. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 1997;225:69-75.
38. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31.
39. Kroll SS, Miller MJ, Schusterman MA, Reece GP, Singletary SE, Ames F. Rationale for elective contralateral mastectomy with immediate bilateral reconstruction. Ann Surg Oncol 1994;1:457-61.
40. de la Rochefordiere A, Mouret-Fourme E, Asselain B, Scholl SM, Campana F, Broet P, Fourquet A. Metachronous contralateral breast cancer as first event of relapse. Int J Radiat Oncol Biol Phys 1996;36:615-21.
41. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995;24:412-9.
42. Lerman C, Daly M, Sands C, et al. Mammography adherence and psychological distress among women at risk for breast cancer. J Natl Cancer Inst 1993;85:1074-80.
43. Bostwick J Preventive mastectomy. Ann Surg Oncol 1994;1:455-6.
44. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
45. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
46. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998;16:2018-24.
47. Garner B. Prophylactic mastectomy: an unnecessary procedure. Ann Surg Oncol 1994;1:453-4.
48. Dean C, Chetty U, Forrest AP. Effects of immediate breast reconstruction on psychosocial morbidity after mastectomy. Lancet 1983;1:459-62.
49. Gabriel SE, Woods JE, O'Fallon WM, Beard CM, Kurland LT, Melton LJ. Complications leading to surgery after breast implantation. N Engl J Med 1997;336:677-82.